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Exercise Compared to SSRIs in the Treatment of Major Depressive Disorder
Tiffany Fletschock, PA-S
Department of Physician Assistant Studies
University of North Dakota School of Medicine and Health Sciences
Abstract
Major Depressive Disorder (MDD) is a common disease seen every
day by primary care providers across the United States. According to
the Centers for Disease Control and Prevention (CDC, 2018), eight
percent of all adults over the age of 20 suffer from depression, and a
study by the American Psychological Association found depressive
disorders to cost roughly $71 billion annually. Today, psychotherapy is
the recommended first-line therapy for treating MDD, but
pharmacotherapy is more commonly used. Alternative forms of therapy
are also being researched in order to avoid the use of medication while
adequately treating the symptoms of MDD. For this review, seven
databases were searched including PubMed, Cochrane Database of
Systematic Reviews, PsycInfo, Cinahl, DynaMed, ClincalKey, and
ScienceDirect from September 1 to November 21, 2018. Works chosen
for review were published after the year 2000 and included randomized
controlled trials (RCTs), systematic reviews, and meta analyses. This
review found several benefits of using exercise to treat MDD while
reducing risks, but exercise alone is not superior in effectiveness to
psychotherapy or pharmacotherapy. Overall, exercise offers the
greatest benefit in reducing MDD symptoms when used as an
augmented therapy to either psychotherapy or pharmacotherapy.
Limitations of this literature review include lack of studies with longevity
or large sample sizes.
Keywords: pathophysiology, exercise, depression, SSRIs, selective
serotonin reuptake inhibitors, Major Depressive Disorder, MDD

Literature Review

Literature Review

Applicability to Clinical Practice

• Pathophysiology of MDD

– Review on escitalopram: more effective than placebo at
decreasing antidepressant effects and preventing relapse

• Depression is one of the most common illnesses seen by primary
care providers today

– Exact pathophysiology remains unknown, but many hypotheses
exist
– Two common theories:
• Biogenic monoamine theory: basis for pharmacologic treatment,
developed after medications unexpectedly increased
monoamine neurotransmitters in the brain by blocking MAOI or
reuptake of neurotransmitters such as serotonin (Fekadu,
Shibeshi & Engidawork, 2016)

– Meta-analysis pooled studies on effectiveness of escitalopram:
significantly reduced depressive symptoms

• Combined source of pathogenesis: Environmental stress
combined with genetic factors act on immunologic and
endocrine responses to cause structural and functional changes
in the brain leading to dysfunction of neurogenesis and
neurotransmitters which ultimately causes symptoms of
depression (Jesulola et al., 2018)

– Cochrane review: benefits associated with SSRIs significantly
greater than that of placebo (Arroll et al., 2009)

• Exercise in the Treatment of MDD
– SMILE study assigned groups to supervised exercise, home
exercise, sertraline, or placebo pill (Blumenthal et al., 2007):
• 41% of participants achieved remission based on HAM-D at the
completion of the study including:
–45% of supervised exercise participants
–40% home exercise
–47% medication

Introduction
• 8% of all adults over the age of 20 suffer from depression
– Women are twice as likely to be affected (CDC, 2018)
• Depression is the
most costly health condition overall with $71
billion spent annually (Winerman, 2017)
6th

• Diagnosis is clinical with the use of screening tools such as the
PHQ-9
• Psychotherapy is the recommended first-line treatment, but
pharmacotherapy is more commonly used due to availability and
convenience (DynaMed, 2018)
• Recent research shows alternative therapies, including exercise,
may be just as beneficial as traditional therapies while avoiding side
effects and limiting the use of medication

Statement of the Problem
• With the increasing cost of medications and potential for high risk
side effects, some providers are recommending alternative
therapies to SSRIs for adult patients diagnosed with mild MDD in
hopes of providing an option that is safer and more cost effective
while providing the same benefit. Further research is needed to
show if exercise and SSRIs are equal in efficacy in the reduction of
symptoms associated with mild MDD in adults.

• Side effects mostly mild to moderate in severity and generally
well-tolerated (Garnock-Jones & McCormack, 2010)

–31% placebo pill
– Cochrane review compared exercise versus control and
pharmacological treatments (Cooney et al., 2013):
• Exercise was moderately more effective than control
–Resistance or resistance + aerobic exercise at a vigorous
intensity was the most effective
• No statistical difference between pharmacologic treatment and
exercise
– Systematic review of RCTs by Danielsson, Noras, Waern, and
Carlsson (2013):
• No statistical difference between exercise and antidepressants

• Response rate 76.9% and remission rate 64%
• Side effects mild to moderate in severity, considered generally
safe (Li, Shen, Lou, & Li, 2017)

Discussion
• Exercise in the Treatment of MDD
– Exercise alone is effective at improving depressive symptoms
(Dunn et al., 2005 & Bartholomew et al., 2005)
– Higher dose and intensity of exercise produced greater effects
(Dunn et al., 2005)
• Exercising at energy expenditure of 17 kcal/kg/wk 3 or more
times per week is just as effective as traditional therapy (Dunn
et al., 2005)
– Exercise also improved positive well-being for a short period of
time (Bartholomew et al., 2005)
– Exercise provided benefits over medication or CBT including:
reduction of risk of mortality from diseases such as cardiovascular
disease and obesity (Dunn et al., 2005)

• CBT is the recommended first-line treatment, but the convenience of
pharmacotherapy has appealed to many causing SSRIs to become
first-line
• SSRIs come with risks, however, and providers should be educated
on alternative forms of therapy that may be of equal benefit without
the added risks of medication
• Benefits of using exercise to treat MDD include minimizing
medication use, avoiding side effects, reducing cost, improving selfconfidence, aiding in weight loss, and improving overall health
• Research on this topic is becoming very popular but current
research includes more women than men and lacks longevity
• At this point in the research, exercise is noted to have a moderate
effect on depression, but after correcting for bias, the effect may
only be small (Cooney et al., 2013)
• Future research should be completed to correct for weaknesses
noted throughout the studies
• Overall, exercise at this point cannot be reported as a superior
therapy over traditional options such as pharmacotherapy or
psychotherapy, but it can be recommended as a beneficial
augmented therapy in addition to traditional treatments for all
patients with MDD
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– Weaknesses of the current research include:
• Lack of blind due to nature of exercise as treatment

•

• Small sample sizes
• Studies lack longevity

•

• SSRIs in the Treatment of MDD
– SSRIs effective at treating mild MDD (Garnock-Jones &
McCormack, 2010, Li et al., 2017, & Arrol et al., 2009)

•

• No statistical difference between exercise versus physical
activity

• SSRIs more effective than placebo (Garnock-Jones &
McCormack, 2010 & Arroll et al., 2009)

•

• Small effect of augmenting exercise to traditional treatment
versus traditional therapy alone

• SSRIs more effective at preventing relapse than placebo
(Garnock-Jones and McCormack, 2010)
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– RCT by Dunn, Trivedi, Kampert, Clark, and Chambliss (2005):
• Exercise at a higher energy expenditure of 17.5kcal/kg/week is
superior to lower energy expenditure
– RCT by Bartholomew, Morrison, and Ciccolo (2005):
• Single episode of exercise compared to 30 minutes of rest
resulted in no improvement in depressive symptoms, but
exercise produced an acute change in positive well-being
• SSRIs in the Treatment of MDD
Figure 2: Adverse effects associated with escitalopram

– Relatively safe with only mild to moderate intensity side effect
noted with increased incidence at higher dosages (Garnock-Jones
& McCormack, 2010
– Weaknesses of the current research include:
• Small sample sizes
• Studies lack longevity
• No specific recommendations regarding dose and duration
– Results varied based on the study:

• Cooney et al. (2013) found exercise to be less effective than
antidepressants or psychological therapy and only moderately
more effective than control

• In adult patients diagnosed with mild MDD in a primary care setting,
does treating with exercise as a stand-alone therapy compared to
treating with SSRIs adequately improve symptoms while minimizing
side effects?

• Danielsson et al. (2013) concluded exercise is beneficial as an
augmentation to medication
– Weaknesses of the current research include:
• Studies lack longevity
Li, G., Shen, Y., Lou, J., & Li, H. (2017). Efficacy of escitalopram monotherapy in the treatment of major depressive
disorder: A pooled analysis of 4 Chinese clinical trials. Medicine, 96(39), e8142.
https://doi.org/10.1097/md.0000000000008142

•
•

•

•

• Exercise Compared to SSRIs in the Treatment of MDD
• Blumenthal et al. (2007) found exercise to be comparable to
antidepressant medication in achieving remission

Research Question

•

• Small sample sizes

•

•

Arroll, B., Elley, C., Fishman, T., Goodyear-Smith, F., Kenealy, T., Blashki, G., … MacGillivray, S.
(2009). Antidepressants versus placebo for depression in primary care. Cochrane Database of
Systematic Reviews, (3), CD007954. https://doi.org/10.1002/14651858.CD007954
Batholomew, J., Morrison, D., & Ciccolo, J. (2005). Effects of acute exercise on mood and wellbeing in patients with Major Depressive Disorder. Medicine and Science in Sports and Exercise,
37(12), 2032-2037. https://doi.org/10.1249/01.mss.0000178101.dd
Blumenthal, J., Babyak, M., Doraiswamy, P., Watkins, L., Hoffman, B., Barbour, K., …
Sherwood, A. (2007). Exercise and pharmacotherapy in the treatment of Major Depressive
Disorder. Psychosomatic Medicine, 69(7), 587-596.
https://doi.org/10.1097/psy.0b013e318148c19a
Centers for Disease Control and Prevention. (2018). Prevalence of depression among adults
aged 20 and over: United States, 2013-2016. Retrieved from https://www.cdc.gov
Cooney, G. M., Dwan, K., Greig, C. A., Lawlor, D. A., Rimer, J., Waugh, F. R., … Mead, G. E.
(2013). Exercise for depression. Cochrane Database of Systematic Reviews, (9), CD004366.
https://doi.org/10.1002/14651858.CD004366.pub6
Danielsson, L., Noras, A. M., Waern, M., & Carlsson, J. (2013). Exercise in the treatment of
major depression: A systematic review grading the quality of evidence. Physiotherapy Theory
and Practice, 29(8), 573-585. https://doi.org/10.3109/09593985.2013.774452
Dunn, A., Trivedi, M., Kampert, J., Clark, C., & Chambliss, H. (2005). Exercise treatment for
depression: Efficacy and dose response. American Journal of Preventative Medicine, 28(1), 1-8.
https://doi.org/10.1016/j.amepre.2004.09.003
DynaMed. (2018). Major depressive disorder (MDD). Retrieved from https://www.dynamed.com
Fekadu, N., Shibeshi, W., & Engidawork, E. (2016). Major depressive disorder: Pathophysiology
and clinical management. Journal of Depression and Anxiety, 6(1), 255.
https://doi.org/10.4172/2167-1044.1000255
Garnock-Jones, K. P. & McCormack, P. L. (2010). Escitalopram: A review of its use in the
management of major depressive disorder in adults. CNS Drugs, 24(9), 769-796.
https://doi.org/10.2165/11204760-000000000-00000
Jesulola, E., Micalos, P., & Baguley, I. J. (2018). Understanding the pathophysiology of
depression: From monoamines to the neurogenesis hypothesis model – are we there yet?
Behavioral Brain Research, 341, 79-90. https://doi.org/10.1016/j.bbr.2017.12.025
Li, G., Shen, Y., Lou, J., & Li, H. (2017). Efficacy of escitalopram monotherapy in the treatment
of major depressive disorder: A pooled analysis of 4 Chinese clinical trials. Medicine, 96(39),
e8142. https://doi.org/10.1097/md.0000000000008142
Winerman, L. (2017). By the numbers: The cost of treatment. American Psychological
Association, 48(3), 80. Retrieved from https://www.apa.org

